Advancing optogenetic therapies for retinal diseases: a regulatory vision

“We are at an exciting stage in our drug development program, and I am committed to advancing Nanoscope’s mission, driving regulatory success, and supporting our pipeline’s growth.”

Jokūbas Leikauskas, Editor, Cell & Gene Therapy Insights, speaks to Ananta Ayyagari, Director of Regulatory and Intellectual Property, Nanoscope Therapeutics Inc. about the regulatory landscape of optogenetic therapies for retinal degenerative diseases, and clinical trial progress. They also discuss the evolving patent landscape for gene therapies, and the regulatory challenges in developing and commercializing such transformative treatments.

Please enter your email to access content Read now